Sun Pharma has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection for chronic weight management in adults. The product, to be sold under the brand name Noveltreat, is indicated as an adjunct to a reduced calorie diet and increased physical activity. This follows a successful Phase III clinical trial conducted in India.
DCGI Approval Received
Sun Pharmaceutical Industries Limited has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. This medication is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity, marking a significant step in addressing obesity in India.
Noveltreat Launch Post-Patent Expiry
The generic semaglutide injection will be launched under the brand name Noveltreat after the expiry of the semaglutide patent in India. This launch follows a review of a Phase III clinical trial conducted in India, ensuring its efficacy and safety for the Indian population.
Dosage and Administration
Noveltreat will be available in five dose strengths: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. The maintenance dose is 2.4 mg administered once weekly via a prefilled pen designed for convenient and accurate dosing.
Addressing Obesity and Diabetes
Obesity and diabetes are significant health challenges in India. GLP-1 based therapies, like Noveltreat, can play a meaningful role in addressing this growing burden. Sun Pharma is committed to improving access to generic semaglutide across the country after the patent expiry. Semaglutide is considered an important scientific advancement for overall metabolic health and should be combined with appropriate lifestyle measures under medical supervision.
Semaglutide for Type 2 Diabetes
In December 2025, Sun Pharma also received DCGI approval for manufacturing and marketing semaglutide injection for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. This will be launched under the brand name Sematrinity, after the expiry of the semaglutide patent in India.
Source: BSE
